Unlocking Earlier Access : IC Fireside Chats - Episode 1
In our debut episode of IC Fireside Chats Omar Ali (Head of Payers, Verpora) and Adam Buckler (VP Innovative Contracting, Verpora) explore one of the most influential value-based agreements in oncology—the Velcade (Bortezomib) contract in the UK.
This case study highlights how a manufacturer navigated pricing negotiations, payer requirements, and access challenges to secure a broad market entry for a breakthrough multiple myeloma therapy.
The discussion examines how an innovative risk-sharing agreement allowed Velcade to overcome a payer impasse, balancing clinical uncertainty with financial guarantees. By offering a performance-based contract—where reimbursement was contingent on treatment success—this agreement reshaped oncology market access strategies and set a precedent for future value-based contracting models.
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
